Integra LifeSciences Holdings Corporation [IART] Q1 2024 Earnings Conference Call May 6, 2024 8:30 AM ET
Company Participants
Jan De Witte - President & CEO
Lea Knight - CFO
Chris Ward - IR
Conference Call Participants
Vik Chopra - Wells Fargo
Steve Lichtman - Oppenheimer
Kristen Stewart - C.L. King & Associates
Robbie Marcus - J.P. Morgan
Matt Taylor - Jefferies
Ryan Zimmerman - BTIG
Joanne Wuensch - Citigroup
Richard Newitter - Truist Securities
Craig Bijou - Bank of America Securities
Jayson Bedford - Raymond James
Drew Ranieri - Morgan Stanley
Operator
Good day, and welcome to the Integra LifeSciences First Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please be advised, today's conference is being recorded.
I would now like to hand the conference over to your speaker, Mr. Chris Ward, Senior Director, Investor Relations. Please go ahead.
Chris Ward
Thank you, Shareen. Good morning, and thank you for joining the Integra LifeSciences First Quarter 2024 Earnings Conference Call. With me on the call are Jan De Witte, President and Chief Executive Officer, and Lea Knight, Chief Financial Officer.
Earlier this morning, we issued a press release announcing our first quarter 2024 financial results. The release and corresponding earnings presentation, which we will reference during the call, are available at Integralife.com under Investors, Events and Presentations, in a file named First Quarter 2024 Earnings Call Presentation.
Before we begin, I want to remind you that many of the statements made during this call may be considered forward-looking. Factors that could cause actual results to differ materially are discussed in the company's Exchange Act reports filed with the SEC and in the release. Also in our prepared remarks, we will reference reported and organic revenue growth and organic revenue growth, excluding Boston. Organic revenue growth excludes the effects of foreign currency, acquisitions, and divestitures. Organic revenue growth, excluding Boston, excludes revenues from products manufactured in our Boston facility in both periods. Management believes that excluding revenue from all products manufactured at the Boston plant, provides useful information when evaluating the company's organic growth because of the unusual nature of the manufacturing stoppage and voluntary global recall. Unless otherwise stated, all disaggregated and franchise-level revenue growth rates are based on organic performance. And lastly, our comments today will include certain non-GAAP financial measures. Reconciliations of non-GAAP financial measures can be found in today's press release, which is an exhibit to Integra's current report Form 8-K filed with the SEC.